Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Kyverna To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 investing Kyverna common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 8, 2024 (the "IPO" or "Offering") and would like to discuss your legal rights, call Faru ...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Kyverna securities pursuant and/or traceable to the Company's offering documents issued in connection wi ...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) (NASDAQ: KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyv ...

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable to Kyverna’s registration statement issued in connection with Kyverna’s initial public offering (“IPO”) held on February 8, 2024, have until February 7, 2025 to seek appointment as lead plaintiff of the Kyverna class action lawsuit. Captioned Rondini v. Kyverna Therapeutics, Inc., No. 24-cv-08869 (N.D. Cal.), ...

LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ: KYTX) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-------------------------------------------------------------------------------------|---------------------------------| | | | | For the transition period from ____________ ...

Exhibit 99.1 Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company Symposium at ACR Convergence 2024 Strong Financial Posit ...

Core Insights - Kyverna Therapeutics has made significant leadership appointments, including Warner Biddle as CEO, to enhance its clinical, commercial, and strategic expertise in cell therapy [1][8] - The company is advancing its KYSA clinical development program, with promising clinical data for KYV-101 in various autoimmune diseases presented at recent conferences [2][3] - Kyverna reported a strong financial position with $321.6 million in cash and equivalents as of September 30, 2024, despite a net loss of $34.3 million for the third quarter [11][12] Leadership and Management Updates - Warner Biddle has been appointed as CEO, bringing over 30 years of experience in commercial and product planning [8] - Christi Shaw and Mert Aktar have joined the Board of Directors, contributing expertise in corporate strategy and manufacturing [8] - Cara Bauer has been appointed as Chief Human Resources Officer to support talent development and organizational growth [8] Clinical Development Highlights - KYV-101 has shown potential in treating stiff-person syndrome, myasthenia gravis, and multiple sclerosis, with data presented at ECTRIMS [3][4] - The company plans to present further clinical data on KYV-101 for lupus nephritis at ACR Convergence 2024, focusing on efficacy, safety, and durability [4][5] - As of November 2024, Kyverna has initiated Phase 2 dosing for KYV-101 and received RMAT and Orphan Drug Designations for multiple indications [6][7] Financial Performance - For Q3 2024, Kyverna reported a net loss of $34.3 million, compared to a net loss of $15.5 million in Q3 2023 [11] - The net cash used in operating activities for the nine months ended September 30, 2024, was $77.2 million, up from $33.8 million in the same period in 2023 [11] - The company ended the quarter with $321.6 million in cash, cash equivalents, and marketable securities [12] Manufacturing and Operational Updates - Kyverna has expanded its manufacturing capacity by partnering with ElevateBio as a second-source supplier for KYV-101 [9] - The company published a study highlighting a 100% manufacturing success rate for KYV-101 in 20 patients, demonstrating a robust manufacturing process [10]

Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapyEMERYVILLE, Calif., Oct. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotech ...

Core Insights - Kyverna Therapeutics presented promising data on KYV-101, a CAR T-cell therapy, at the ECTRIMS Congress, highlighting its efficacy and safety in treating neuroinflammatory diseases such as stiff-person syndrome, myasthenia gravis, and multiple sclerosis [1][2][3] Group 1: Clinical Data and Efficacy - Case reports from 11 patients showed that KYV-101 led to improved mobility and reduced autoantibody levels in stiff-person syndrome, with effects lasting over one year for some patients [3] - In myasthenia gravis, three patients exhibited reduced pathogenic antibody levels and sustained disease control, with two patients maintaining results for over one year [3] - Five patients with multiple sclerosis, who previously failed anti-CD20 treatments, demonstrated a significant reduction in oligoclonal bands, indicating potential disease progression reduction [3] Group 2: Clinical Trials and Research - Kyverna is conducting three ongoing Phase 2 trials for KYV-101: KYSA-6 for myasthenia gravis, KYSA-7 for multiple sclerosis, and KYSA-8 for stiff-person syndrome [2][9] - The company presented three posters detailing the design and methods of its clinical trials at the ECTRIMS Congress, focusing on the activity and manufacturing of KYV-101 [4] Group 3: Company Vision and Future Potential - Kyverna's CEO emphasized the potential paradigm shift in treating neuroinflammatory diseases through deep B-cell reset, aiming to address significant unmet medical needs [2] - The company aims to leverage the emerging data to accelerate the development of transformative therapies for patients suffering from autoimmune diseases [2][9]